Natasha Zarich

Natasha Zarich

Auto-generated profile, based on publicly available information

Natasha Zarich

Unidad Funcional de Investigación de Enfermedades Crónicas (UFIEC) and CIBERONC, Instituto de Salud Carlos III, Majadahonda, Spain

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2006 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
LGL González-Santiago
L González-Santiago
YSY Suárez
Y Suárez
NZN Zarich
N Zarich
MMM J Muñoz-Alonso
M J Muñoz-Alonso
ACA Cuadrado
A Cuadrado
AMAlberto Muñoz
Alberto Muñoz

1 March 2008 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
MMMaría J. Muñoz-Alonso
María J. Muñoz-Alonso
LGLaura González-Santiago
Laura González-Santiago
NZNatasha Zarich
Natasha Zarich
TMTeresa Martínez
Teresa Martínez
EAEnrique Alvarez
Enrique Alvarez
AMAlberto Muñoz
Alberto Muñoz
Melanoma is the most aggressive skin cancer and a serious health problem worldwide because of its increasing incidence and the lack of satisfactory chemotherapy for late stages of the disease. The marine depsipeptide Aplidin (plitidepsin) is an antitumoral agent under phase II clinical development against several neoplasias, including melanoma. We report that plitidepsin has a dual effect on the human SK-MEL-28 and UACC-257 melanoma cell lines; at low concentrations (≤45 nM), it inhibits the cell cycle by inducing G1 and G2/M arrest, whereas at higher concentrations it induces apoptosis as assessed by poly-(ADP-ribose) polymerase cleavage and the appearance of a hypodiploid peak in flow cytometry analyses. Plitidepsin activates Rac1 GTPase and c-Jun NH2-terminal kinase (JNK). In addition, it induces AKT and p38 mitogen-activated protein kinase (MAPK) phosphorylation. By using inhibitors, we found that JNK and p38 MAPK activation depends on Rac1 but not on phosphatidylinositol 3-kinase (PI3K), whereas AKT activation is independent of Rac1 but requires PI3K activity. Plitidepsin cytotoxicity diminishes by Rac1 inhibition or by the blockage of JNK and p38 MAPK using 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole (SB203580), but not by PI3K inhibition using wortmannin or 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). It is remarkable that plitidepsin and dacarbazine, the alkylating agent most active for treating metastatic melanoma, show a synergistic antiproliferative effect that was paralleled at the level of JNK activation. These results indicate that Rac1/JNK activation is critical for cell cycle arrest and apoptosis induction by plitidepsin in melanoma cells. They also support the combined use of plitidepsin and dacarbazine in in vivo studies.

1 August 2006 in Molecular Biology of the Cell
Verified
Journal Article
Closed access
NZNatasha Zarich
Natasha Zarich
JOJosé Luis Oliva
José Luis Oliva
NMNatalia Martínez
Natalia Martínez
RJRocío Jorge
Rocío Jorge
ABAlicia Ballester
Alicia Ballester
JRJosé M. Rojas
José M. Rojas
HSos1 is a Ras guanine-nucleotide exchange factor. It was suggested that the carboxyl-terminal region of hSos1 down-regulates hSos1 functionality and that the intrinsic guanine-nucleotide exchange activity of this protein may be different before and after stimulation of tyrosine kinase receptors. Using different myristoylated hSos1 full-length and carboxyl-terminal truncated mutants, we show that Grb2 function accounts not only for recruitment of hSos1 to the plasma membrane but also for modulation of hSos1 activity. Our results demonstrate that the first two canonical Grb2 binding sites, inside the carboxyl-terminal region of hSos1, are responsible for this regulation. Following different approaches, such as displacement of Grb2 from the hSos1-Grb2 complex or depletion of Grb2 levels by small interfering RNA, we found that the full-length Grb2 proteins mediate negative regulation of the intrinsic Ras guanine-nucleotide exchange activity of hSos1.

19 August 2010 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JOJulen Oyarzabal
Julen Oyarzabal
NZNatasha Zarich
Natasha Zarich
MAMaría Isabel Albarran
María Isabel Albarran
IPIrene Palacios
Irene Palacios
MUManuel Urbano-Cuadrado
Manuel Urbano-Cuadrado
JBJames R. Bischoff
James R. Bischoff

10 August 2005 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
OMOlga Millán
Olga Millán
DRDaniel Rico
Daniel Rico
Hector PeinadoHector Peinado
Hector Peinado
NZNatasha Zarich
Natasha Zarich
KSKonstantinos Stamatakis
Konstantinos Stamatakis
Lisardo BoscáLisardo Boscá
Lisardo Boscá
The effect of prostaglandins on the development of papillomas has been investigated in mice receiving prostaglandins E 2 (PGE 2 ) or the cyclopentenone 15-deoxy-Δ 12,14 -PGJ 2 (15dPGJ 2 ) topically, using the 7,12-dimethylbenz[ a ]anthracene (DMBA)-induced tetradecanoylphorbol acetate (TPA)-promoted model of skin carcinogenesis. The presence of 15dPGJ 2 during DMBA and TPA treatment inhibited apoptosis and increased the rate, number, size and vascularization of the papillomas, some of them progressing into carcinomas. Moreover, skin sections from mice treated for one week with DMBA and 15dPGJ 2 showed a much reduced rate of apoptotic cells, and an enhanced expression of vascular epithelial growth factor when compared with animals receiving DMBA, with or without PGE 2 . The analysis of molecular events in the MCA3D keratinocyte cell line showed that 15dPGJ 2 activated Ras and improved cell viability by inhibiting DMBA-dependent apoptosis. In addition to this, cell adhesion was impaired in MCA3D keratinocytes co-treated with 15dPGJ 2 and DMBA, at the same time when the expression of cyclooxygenase-2 (COX-2) was observed under these conditions. These effects mediated by 15dPGJ 2 might contribute to understand the role of COX-2 metabolites in carcinogenesis, leading to an increase of cell viability after mutagenic injury and therefore in the progression of tumors.

1 November 2002 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
RJRocı́o Jorge
Rocı́o Jorge
NZNatasha Zarich
Natasha Zarich
JOJosé Luis Oliva
José Luis Oliva
MAMarta Azañedo
Marta Azañedo
NMNatalia Martı́nez
Natalia Martı́nez
JRJosé M. Rojas
José M. Rojas
The protein hSos1 is a Ras guanine nucleotide exchange factor. In the present study, we investigated the function of the amino-terminal region of the hSos1 protein, corresponding to the first 600 residues, which includes the Dbl and pleckstrin homology (DH and PH) domains. We demonstrated, using a series of truncated mutants, that this region is absolutely necessary for hSos1 activity. Our results suggest that the first 200 residues (upstream of DH domain), which we called the HF motif on the basis of their homology with histone H2A, may exert negative control over the functional activity of the whole hSos1 protein. In vitro binding analysis showed that the HF motif is able to interact specifically with the PH domain of hSos1. The amino-terminal region of hSos1 may be associatedin vivo with an expressed HF motif. These findings document the existence of the HF motif located upstream of the DH domain in the hSos1 protein. This motif may be responsible for the negative control of hSos1, probably by intramolecular binding with the PH domain.